FDA approves Roche’s second CD20xCD3 bispecific in certain lymphomas

The FDA grant­ed ac­cel­er­at­ed ap­proval to Genen­tech’s CD20xCD3 bis­pe­cif­ic for pa­tients with a cer­tain type of non-Hodgkin’s lym­phoma on Thurs­day night, as the Roche unit and Gen­mab pro­mote dif­fer­ent ben­e­fits to their po­ten­tial­ly com­pet­i­tive med­i­cines.

Genen­tech’s Columvi and Ab­b­Vie/Gen­mab’s Ep­kin­ly, which was green­lit last month, are now ap­proved as third-line treat­ments for re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma, which is the most com­mon form of non-Hodgkin’s lym­phoma in the US.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN